PF-AtlasКлинические испытания › NCT05755308

Faecal Microbiota Transplantation to Ameliorate Nintedanib-induced Diarrhea in Patients With Idiopathic Pulmonary Fibrosis

Autologous FMT · Не указано

ID реестра
NCT05755308
Фаза
Не указано
Статус
Неизвестно
Препарат / вмешательство
Autologous FMT
Спонсор
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Начало
2023-10
Набор участников
114
Центры
1

Об исследовании

This is a multicentric, randomised, double-blind, placebo-controlled study that will consist of two consecutive phases: 1. First phase: faecal samples will be collected in patients diagnosed with Idiopathic pulmonary fibrosis treated with nintedanib. 2. Second phase: double-blind, randomised, clinical trial of autologous faecal microbiota transplantation (FMT) vs placebo in Idiopathic pulmonary fibrosis patients who will experience nintedanib-induced diarrhea within 8 weeks of baseline visit. Follow-up visits will be scheduled at 1, 4 and 12 weeks after randomization. The main aim of the study is to assess the efficacy of FMT in ameliorating diarrhea experienced by patients with idiopathic pulmonary fibrosis treated with nintedanib.

Открыть NCT05755308 на ClinicalTrials.gov →

Связанные материалы

Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT05755308 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.